Indication intelligence, analysis and sector perception

RegMed Investors: Verve Therapeutics (VERV) amended and restated collaboration and license Agreement with Beam Therapeutics (BEAM)

July 7, 2022 12:20pm

The original agreement provided Verve with an exclusive, worldwide, sublicensable license under certain of Beam’s base editing, gene editing, and delivery technologies for applications against four liver-mediated cardiovascular disease targets and two undisclosed gene targets.

Under the amendment, Beam granted Verve a license toward an additional liver-mediated cardiovascular disease target. VERV will be responsible for developing and commercializing products targeting such genes, subject to BEAM’s opt-in right.

Following the final dosing of a patient in the P1 trial of a licensed product for such gene, Beam can opt-in to share 35% of development costs, commercializing costs, and profits. If Beam does not opt-in, it would be entitled to receive milestones and royalties.

Verve granted Beam an exclusive license under Verve’s intellectual property, including under Verve’s GalNAc-LNP delivery technology, relating to a preclinical program developed by Verve, (initially announced in April 2019).

In addition, the amended agreement grants Beam, on a target-by-target basis, the option to obtain a non-exclusive license to Verve’s GalNAc-LNP delivery technology.

Beam would owe Verve a fee upon exercise of each option, certain milestones, and low single-digit royalties.

BEAM stock was up +$5.14 or +11.28% to $50.70 having closed at $45.56, and VERV stock was up +$1.50 or +8.56% to $19.09 having closed at $17.59 on Wednesday. <Benzinga>

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.